The company intends to be breakeven at q2-3 2016.
If fully diluted, the company will have 75 million shares Max.
Compared to last quarterly sales and the market cap adjusted to 70 million shares, the market cap (at 70 m shares) would equal the revenues of 3 quarters. That is still way undervalued!
Please note the following:
1. Quarterly revenues are growing significantly quarter after quarter
2. The company did cut costs by restructuring in personnel, which would equal a cut in yearly costs by 6 million dollar.
3. FDA decision is coming in May. If you looked at the last company presentation, the company believes Europe will bring 20% and the US will bring 80% of revenues.
Therefore it is my opinion that the company will be at their IPO share price of $4/share by by 2017 or sooner and be above $1 by the end of May.
News 
Market Data 
Discover 
